BNP Paribas Asset Management
TVTX icon

BNP Paribas Asset Management’s Travere Therapeutics TVTX Stock Holding History

BNP Paribas Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.3K Buy
1,390
+288
+26% +$8.61K ﹤0.01% 1807
2025
Q4 		$42K Buy
1,102
+418
+61% +$13.6K ﹤0.01% 1718
2025
Q3 		$16K Hold
684
– – ﹤0.01% 1481
2025
Q2 		$10K Buy
+684
New +$11.3K ﹤0.01% 1789
2016
Q1 		– Sell
-328,294
Closed -$6.33M – 1086
2015
Q4 		$6.33M Buy
328,294
+23,181
+8% +$463K 0.05% 397
2015
Q3 		$6.18M Buy
305,113
+63,620
+26% +$1.88M 0.05% 408
2015
Q2 		$8.01M Buy
+241,493
New +$6.61M 0.06% 381

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BNP Paribas Asset Management's TVTX Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Travere Therapeutics (TVTX) stake by 26% in Q1 2026, buying an estimated $8.61K and bringing the position to 1,390 shares worth $41.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1807.

BNP Paribas Asset Management first reported a position in TVTX in Q2 2015 and has held it in 7 quarters since. The position peaked at $8.01M in Q2 2015. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • BNP Paribas Asset Management held 1,390 shares of Travere Therapeutics worth $41.3K as of Q1 2026.
  • BNP Paribas Asset Management bought 288 Travere Therapeutics shares in Q1 2026, an estimated $8.61K.
  • Travere Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1807 holding.
  • BNP Paribas Asset Management first reported a position in Travere Therapeutics in Q2 2015 and has held it in 7 quarters since.
  • BNP Paribas Asset Management's Travere Therapeutics position peaked at $8.01M in Q2 2015.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.